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Abstract Cervical cancer is usually treated by surgery, with
the more advanced cancers requiring adjuvant chemotherapy
or radiotherapy. The location of the cervix makes it easily
accessible through the vagina for the localised delivery of
chemotherapeutic drugs. Localised delivery has the advantage
of direct delivery to the site of action resulting in a lower dose
having to be required and a reduction in systemic side effects.
This approach would be advantageous for fertility sparing
surgery, whereby localised delivery could be used to reduce
tumour size allowing for a much smaller tumour to be re-
moved, reducing the risk of preterm birth. Furthermore, local-
ised delivery could be used after surgery to reduce the risk of
recurrence, which is significantly higher in fertility sparing
surgery compared to standard surgery. In this paper, we dis-
cuss the number of vaginal dosage forms that have investigat-
ed for this purpose, including tablets, rings, bioadhesive and
cervical caps. APIs under investigation have ranged from
well-established chemotherapeutic drugs to more experimen-
tal compounds.
Keywords Cervical cancer . Fertility sparing surgery .
Neoadjuvant chemotherapy .Vaginaldrugdelivery .Localised
drug delivery
Introduction
Cervical cancer is the third most prevalent cancer in women
globally, with 528,000 cases a year [1]. A total of 85% of cases
arise in developing countries due to a lack of cervical cancer
prevention and control programs. Where women have access
to resources capable of detecting and treating precancerous
lesions, the number of cases is reduced by approximately
80% [2]. The sexual transmission of the human papillomavi-
rus (HPV) is the main cause of cervical cancer. Other risk
factors, such as multiple sex partners, smoking, sexual activity
at a young age, multiple pregnancies, oral contraceptives and
other sexually transmitted infections, can also contribute to
cervical cancer [3, 4].
Epidemiology
In 2012, there was an estimated 266,000 deaths from cervical
cancer worldwide [1]. There is a remarkable disparity in the
effects of disease between different parts of the globe [5]. The
most impacted world area is Eastern Africa where the age-
standardised mortality rate is 27.6 per 100,000. The least im-
pacted world area is Western Asia where the age-standardised
mortality rate is 1.9 per 100,000. Since cervical cancer is a
preventable disease and screening programs are common-
place, the rates of mortality and incidence have dropped con-
siderably in the developed world since the mid-seventies. For
example, in Denmark, the age-standardised incidence rate has
fallen from 70.9 per 100,000 to 19.2 per 100,000 over four
decades [6]. The mortality rate for the disease in Denmark
stands at 2.6 per 100,000 [7]. Denmark began a national
roll-out of cervical screening in 1967 following on from a
small population-based study in a single municipality begun
in 1962 [8]. The total roll-out completed in 1996. A recent
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study determined that the Danish screening program
prevented 51.7% of the projected cumulative incidence cases
over the period of 1961 to 2010 [6], which would be in the
region of 27,506 cases.
African nations are faring much worse in cervical cancer
prevention as African countries constitute 16 of the top 20
countries with the highest incidence rates of the disease [1].
Malawi has the highest incidence rate of 75.9 per 100,000 in
the world, with a mortality rate of 49.8 per 100,000. The
country has had an active prevention program since the late
eighties [9], and almost all the country’s health districts pro-
vide screening services using the WHO-approved visual in-
spectionwith acetic acid (VIA) [10]. However, very few of the
4.50 million at-risk women were screened with participation
being 3.7% urban women and 2.5% rural women. One possi-
bility for low participation in the national screening program
may be due to roll-out having been restricted to district hos-
pitals with only limited extension of the services to local
health centres. An in-depth study by the University of
Malawi cited a lack of adequately trained healthcare staff
and that the existing staff were not sufficiently distributed or
well-supervised [11]. The study described a lack of basic
screening and treatment equipment and medical consumables
in the health facilities running providing services.
However, the Malawi experience of a national screening
program cannot easily be overlaid onto other African and low-
resource countries since there are infrastructural limitations
and cultural barriers unique to each country and region.
Alliance for Cervical Cancer Prevention (ACCP) has made a
number of recommendations for improving the efficiency and
quality of cervical cancer screening and treatment in low-
resource settings with the aim of decreasing high mortality
rates [12]. The AACP study included the analysis of data from
a wide variety of world areas. The AACP makes a number of
recommendations, including a move away from cytology-
based screening towards HPV-DNA testing that is more
cost-effective and laboratory-independent. The study also rec-
ommends a single visit approach in which the patient is tested
and treated on the same occasion, thus reducing the high loss
to follow-up rates currently experienced. Treatment would
come in the form of cryotherapy for precancerous lesions.
Limited access to the two expensive HPV vaccines
(Gardasil® and Cervarix®) may also be a factor in the higher
mortality rates in low-resource settings [5], but there is of yet
no data to affirm primary prevention of HPV-related cancers
for the large populations that have rolled-out a vaccine
program.
Staging
Cervical cancer, as with most cancers, has been classified into
stages so as to better manage patients and standardise
treatment [13]. In carcinoma in situ (stage 0), abnormal cells
are found in the innermost lining of the cervix and may be-
come cancerous and spread into nearby normal tissue. Stage I
cancers are only located at the cervix and depending on the
amount of cancer found can be divided into stages IA and IB,
which can be sub-divided into stages IA1, IA2, IB1 and IB2
depending on the size of the tumour. Stage II cancers will have
spread beyond the cervix, but not as far as the pelvic wall or
the lower third of the vagina and are divided into IIA and IIB,
based on how far the cancer has spread. In stage III, the cancer
has spread to the lower third of the vagina and/or pelvic wall
and may also have started to cause kidney problems. Like
stage II, stage III is also divided into stages IIIA and IIIB,
based on how far the cancer has spread. By stage IV, the
cancer has spread to the bladder, rectum or other parts of the
body. Stage IV can also be divided into IVA and IVB, depend-
ing on where the cancer is found. In stage IVA, the cancer has
spread to nearby organs such as the bladder and rectum, while
in stage IVB, the cancer may be found in other parts of the
body, such as the liver, lungs, bones or distant lymph nodes.
There are currently two approaches used to prevent cervical
cancer from developing to an advanced stage (stage IIB): (1)
the distribution of HPV vaccines that are mainly directed
against HPV types 16 and 18 [14] and (2) screening methods,
such as Papanicolaou test (Pap smear), which involves the
collection of exfoliated cells from the cervix, which are then
examined for cellular abnormalities enabling the identification
of CIN before they begin to develop into cervical cancer [15].
Treatment options
Following the diagnosis of cervical cancer, there are many
different treatment options available all of which depend on
the stage of the cancer and the health of the patient. Pre-
invasive (stage 0) and early stage cancers (IA to IIA1) are
treated using surgery such as loop electrosurgical excision
procedure (LEEP), large loop excision of the transformation
zone (LLETZ) or cone-shaped excision, which involve the
removal of a small amount of cervical stroma [16], or a hys-
terectomy (removal of the whole uterus including part of the
vagina) and removal of the lymph nodes or using radiation
therapy. Patients treated using surgery may also receive radi-
ation therapy in order to reduce the risk of relapse. Larger
early stage cancers (IB2 and IIA2) are treated with either ra-
diation therapy or chemotherapy or a hysterectomy followed
by radiation therapy, or chemotherapy followed by a hyster-
ectomy. Advanced stage cancers (IIB to IVB) are treated using
radiation therapy and chemotherapy [17]. Cisplatin is deemed
the single most active agent against cervical cancer [13]. The
options for chemotherapy are cisplatin once a week during
radiation or cisplatin with 5-fluorouracil once every 4 weeks
during radiation.
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Radical hysterectomy
Hysterectomy is an all-encompassing term that is used to de-
scribe surgical procedures of various degrees of radicality.
Treatment of cervical cancer by surgical intervention has a
long history dating well back into the 1800s, and significant
refinement in approach was observed throughout the first half
of the last century to improve post-operative mortality rates
and quality of life [18]. Yet, the first attempt to have a
standardised form of surgical treatment employing classifica-
tion has only been a fairly recent development [19]. Surgical
classification aims to provide a basis for surgery taking into
account a number of prognostic considerations aiming tomax-
imise the removal of cancerous tissue but also to limit damage
to important cervicovaginal structures and function. Surgeons
take consideration of tumour depth and spread, status of the
surrounding lymph nodes and lymphovascular space invasion
[18].
The first widely adopted classification system dates to
1974 and the work of a group of surgeons at MD Anderson
in Texas [19]. This system adopted five classes of radical
hysterectomies that increased in radicality up the scale. Class
I involved removal of the cervical tissue only, while class V
involved the removal of the cervix, pelvic lymphatics and
extensive amounts of paravaginal, parametrial and periureteral
tissues, plus sections of the ureter and bladder. The system
lacked clear anatomical definitions and did not describe
methods for nerve preservation. Nerve preservation is a key
consideration area since it has been shown to provide a sig-
nificant reduction in morbidities associated with radical hys-
terectomy, including loss of sexual, bladder and anorectal
functions [20–24], and reduced vaginal blood flow [25].
However, this approach may limit the curative effect of sur-
gery since the remaining nerves and connective tissue may be
sites for local recurrence. Two recent systematic reviews were
both inconclusive in this regard due to limitations of previous
studies [26, 27].
Critical of the previous classification system, Querleu and
Morrow devised their own in 2008 with the desire of provid-
ing a simpler, clearer approach that reduced excessive vaginal
resection and comprehensively preserved more nerves [28].
This newer system adopts clear anatomical markers by
adopting international definitions and creates four types of
classifications: (a) minimum resection of paracervix, (b) tran-
section of paracervix at the ureter, (c) transection of paracervix
at junction with internal iliac vascular system and (d) laterally
extended resection. The system considers lymph node resec-
tion separately and is based around the stable arterial anatomy
for orientation as opposed to the older system’s use of spatial
descriptors. Vaginal resection and ureter management are
modifiable components of each type and are to be determined
by the surgeon for each individual case. A follow-up consen-
sus paper adds to the original by describing individual three-
dimensional parametrial resections for a number of the classi-
fication types [29].
Localised delivery of chemotherapeutic drugs
Localised delivery of chemotherapeutic drugs offers a number
of advantages over systemic administration: (1) direct delivery
to the site of action, (2) a lower dose being required, (3) a
reduction in systemic side effects and (4) increased drug sta-
bility as it remains in the delivery device until released [30].
The location of the cervix makes it easily accessible through
the vagina and allows for the non-invasive implantation of a
localised drug delivery device or formulation adjacent to the
cancerous tissue either before resection, to reduce tumour size,
or after resection to reduce the risk of recurrence. Furthermore,
cervical cancer is an excellent choice for localised drug deliv-
ery as due to regular screening approximately 50% of cases
are diagnosed when the cancer is confined to the cervix (local-
ised; stage I), while about 35% of cases are diagnosed after the
cancer has spread to the lymph nodes (regional; stage II/III).
Therefore, only about 10% of cases are diagnosed when the
cancer has already spread to distant regions (metastasized;
stage IV). Localised drug delivery is only an option for stage
0 (precancerous), stage I, which are still confined to the cervix
and early stage II cancers, which have spread beyond the
cervix, but not as far as the pelvic wall or the lower third of
the vagina. For late stage II through to stage IV, cervical can-
cer systemic delivery of chemotherapeutic drugs would be
required to ensure that the drug reaches those cancer cells
which have spread to other parts of the body such as the
bladder, lungs or lymph nodes (Fig. 1).
Vaginal drug delivery for the localised treatment
of cervical cancer
The vagina has been used to deliver drugs for a range of
clinical and research applications, including contraception,
vaginal infections and HIV prevention, with many different
vaginal formulations such as gels, creams, pessaries, suppos-
itories, diaphragms, rings, films and tablets available [31–39].
Furthermore, a number of these delivery systems have been
investigated for the localised delivery of chemotherapeutic
drugs to the cervix [40–44]. When considering the vaginal
route of administration for localised delivery, two key areas
need to be considered: (1) the nature of the drug being admin-
istered and (2) the uterine first pass effect.
The nature of the drug is important when it comes to choos-
ing the dosage form that will be used for delivery. For exam-
ple, conventional vaginal rings are only capable of delivering
small hydrophobic molecules due to the type of polymers
which are used to manufacture vaginal rings. For a drug to
be released from a vaginal ring, it must first dissolve in the
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polymer matrix (which is manufactured from hydrophobic poly-
mers such as silicone and ethylene-vinyl-acetate copolymer) and
subsequently diffuse through the polymer (large molecules will
not diffuse through the polymermatrix). However, once the drug
leaves the vaginal ring, it must dissolve in the aqueous vaginal
fluid and thusmust have some aqueous solubility. Therefore, it is
recommended that for a drug to be formulated into a vaginal ring,
it must have a molecular weight of less than 1000 Da and a
partition coefficient (log P) of between approximately 2 and 4.
For other dosage forms such as vaginal gels and tablets, the
molecular weight of the drug is not so critical in relation to drug
release, whereas the log P is critical, because the drug needs to be
hydrophilic enough to dissolve in vaginal fluid, but hydrophobic
enough to be absorbed into vaginal tissue and the site of action.
The uterine first pass effect is where vaginally administered
drugs preferentially accumulate in the uterus through a direct
transport mechanism [45, 46]. The effect has been described
for a number of drugs, principally progesterone [47, 48] and
other steroids [49–51]. Direct vaginal-to-uterine transport is
thought to occur via the counter-current exchange of drug
through vein-to-artery diffusion [52]. The phenomenon is driven
by the close proximity of a dense venous network in the upper
vagina to the uterine artery, in which the high concentration of
drug in the vaginal blood vessels will diffuse across into the
adjoining uterine artery. Blood circulation is a key mechanism
of the uterine first pass effect, since plasma drug concentrations
have been shown to be significantly higher in the uterine artery
than in the radial artery [48]. Such direct transport has the poten-
tial to be a major issue for therapies required to act locally in the
vagina as the drugs could be transported away, thus unable to
achieve effective concentration levels at the site of action. Since
the uterine first pass effect only occurs in the upper third of the
vagina [49], the phenomenon may significantly hinder localised
delivery to the cervix. Therefore, larger doses may be needed to
achieve effective drug levels at the cervix. Furthermore, with the
accumulation of the drug in the uterus and an increase in the
direct transport of the drug from the vagina to the uterus as a
result of higher concentrations in the vagina, toxicity could be a
potential problem, especially with chemotherapeutic drugs.
Topical formulations
Localised delivery does not currently form part of standard
treatment of cervical cancer. However, off-label use of both
5-fluorouracil (5-FU) and imiquimod (IMQ) topical creams
can form part of treatment of genital intraepithelial neoplasia
Fig. 1 Typical vaginal dosage forms for the delivery of chemotherapeutic
drugs a ethylene vinyl acetate copolymer vaginal ring with an outer
diameter of 54 mm and a cross-sectional diameter of 4 mm. b Nano-
encapsulated disulfiram particles (1 μm scale). c Bilayer vaginal tablets
(13 mm diameter and 4 mm thick) containing a disulfiram loaded sustained
layer and copper (II) sulphate immediate release layer. d
Hydroxyethylcellulose based vaginal gel, typical 2 g application on Petri
dish
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at the discretion of the treating physician [53–57]. 5-FU is an
antimetabolite drug that has two mechanisms of action—inhi-
b i t ion of the thymidyla te synthase enzyme and
misincorporation into DNA and RNA [58]. Since the drug’s
first synthesis in the fifties, it has been widely used to treat a
number of cancers, most notably colorectal. Topical formula-
tion of the drug is used to treat skin cancer and HPV-related
warts, lesions and neoplasia [55, 59–61]. Rahangdale et al.
conducted a clinical study to evaluate the efficacy of 5% 5-
FU cream for intravaginal treatment of CIN II [62]. In the
study, 60 women with CIN II were randomised to two groups,
treatment (n = 31) and observation (n = 29). There was no
placebo group. The group undergoing treatment was told to
apply 2 g Efudex® cream at night to the cervix using a vaginal
applicator and to place a tampon to maintain cream at the
cervix. Efudex® cream is a treatment for multiple actinic or
solar keratosis. Dosing was once every 2 weeks for a total of
eight doses. The results of this study clearly showed a signif-
icant increased likelihood of CIN II regression for patients
treated with topical 5-FU cream. A total of 93% of the treated
group demonstrated regression compared to 56% for the ob-
served group. After 6 months, the treated group was twice as
likely to be both HPV negative and clear of neoplasia. The
study also demonstrated that the dosing regimen of 5-FU
cream was well tolerated. However, the clinicians caution that
there was potential increased risk of sexually transmitted in-
fections due to the treatment, and the patients had to under-
stand the importance of effective birth control during
treatment.
Imiquimod is an immunomodulator which triggers a local
immune response effective against both cancer cells and vi-
ruses [63]. The drug increases the potency of natural killer
cells by increasing the levels of cytokines in a local area.
The drug also boosts the adaptive immune systems, increasing
the action of both tumour-specific T cells and antibody pro-
ducing B cells. Topical IMQ cream is used to treat basal cell
carcinoma, actinic keratosis and genital warts. Off-label treat-
ments have been investigated for intraepithelial neoplasia of
the vulva and vagina [64]. Two clinical studies have been
reported on the use of the cream to treat high-grade CIN (II/
III). Grimm et al. investigated the off-label use of topical IMQ
cream as an alternative to surgical intervention [65]. The study
enrolled 59 patients into two randomised groups, placebo
(n = 29) and treated (n = 30). Treatment involved vaginal
suppositories of Adeps solidus containing 6.25 mg IMQ. For
the first 2 weeks, patients applied one suppository per week;
for weeks 3 and 4, patients applied two suppositories weekly;
and for the final 12 weeks, the patients applied three suppos-
itories weekly. The suppositories were applied prior to going
to bed. The main outcome was efficacy of the treatment,
which was defined as histological regression of to CIN I or
less within 4 weeks of treatment cessation. The primary end
point was observed for 73% of the treated group, compared to
39% of the placebo group. A total of 60% of the treated group
were also HPV negative compared to only 14% of the placebo
group post-treatment. Indeed, IMQ treatment also demonstrat-
ed a 60% clearance against the high-risk, aggressive HPV-16
strain compared to 6% for the placebo arm.
The second clinical study by Koeneman et al. began in
January 2015 [66]. The study aimed to enrol 140 women with
CIN II/III randomised to two groups, IMQ treatment (n = 70)
and standard treatment (n = 70). Treatment would be over
16 weeks involving vaginal application of 5% IMQ cream
(12.5 mg) three times per week. Primary end point was de-
fined as regression to CIN I or less at 4 weeks after treatment
cessation. Patients were to be monitored at regular intervals up
to 24 months after treatment. However, the study had to be
preliminarily stopped in May 2016 due to lagging inclusions
of women who had strong preferences for either one of the
two treatments. A study by the authors found that in most
cases, women prefer the standard LLETZ treatment as it pro-
vides a fast and effective treatment of high-grade CIN [67]. On
the other hand, women hoping to maintain the strongest
chance of future pregnancy wished to pursue the non-
surgical IMQ treatment. The trial has now converted to an
open-label, non-randomised, controlled study to evaluate effi-
cacy of topical IMQ treatment [68]. The clinical team aims to
develop a biomarker profile to predict patients who would
have the best clinical response to IMQ treatment.
Recruitment began in November 2016.
Vaginal gels
A range of other vaginal dosage forms and devices have been
investigated for the localised treatment of cervical cancer.
Bilensoy et al. developed thermosensitive mucoadhesive gels
containing 5-FU in a complex with cyclodextrin (CD) [69].
The gels had a lower viscosity at room temperature and thus
were easier to administer to the cervix through the vagina.
However, upon administration and exposure to the higher
temperature in the body, they increased in viscosity, providing
a sustained release of the 5-FUCD complex (5-FU:CD), while
their mucoadhesive properties ensured longer residence at the
cervix. Furthermore, cytotoxicity studies demonstrated that 5-
FU:CD, which only contained 25% 5-FU, was equally effec-
tive against HeLa human cervical carcinoma cells as the same
dose of free 5-FU, indicating better therapeutic efficacy using
a lower dose of 5-FU [69]. Debata et al. developed a
curcumin-based vaginal cream that had the potential to elim-
inate a variety of HPV positive cervical cancers and had no
adverse side effects when tested in mice [70]. A study dem-
onstrated that a 1% cidofovir vaginal gel was effective against
CIN III [71]. Seven of the 15 patients tested showed complete
inhibition of the cervical dysplasia lesions after only three
applications (every other day), while five showed a partial
response, characterised by the persistence of CIN II-III
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lesions, one patient had a lower grade dysplasia (CIN I) and
two patients had no response. The effect was specific and no
tissue other than the dysplastic epithelium was affected by the
treatment [71]. A phase II double-blind, placebo-controlled
study of a 1% cidofovir vaginal gel in HPV positive patients
demonstrated that no patients in cidofovir group experienced
progression of the disease compared to 45% of patients in the
placebo group [72]. These two clinical studies taken together
demonstrate the benefits of using a vaginal gel, for localised
drug delivery, to stop progression to cervical cancer by either
eradicating or down staging precancerous CIN or stopping
HPV infections progressing to CIN.
Vaginal tablets
Baffoe et al. describe the manufacture and testing of both
immediate and sustained release vaginal tablets containing
130 mg of the drug disulfiram [73]. Disulfiram has been used
safely in the clinic for many years to treat alcoholism and has
shown potential anti-tumour activity as it can induce apoptosis
in some cell lines and reduce cell growth in certain tumours
[74]. An anticancer effect has been demonstrated in prostate
cancer, breast cancer, lung cancer, leukaemia and cervical ad-
enocarcinoma [75–83]. Baffoe et al. demonstrate that
disufiram has a dose-dependent inhibition of the HeLa cervi-
cal cancer cell line with an IC50 value of 124.3 nM, which is
significantly more therapeutic than cisplatin with an IC50 val-
ue of 2.2 μM against the same cell line. Furthermore, they
show, using a bio-relevant dissolution model, that their imme-
diate and sustained release tablets can release disulfiram at
25,000 to 35,000 times its IC50 concentration [73]. A
multicentre observational study in 256 patients with histolog-
ically proven CIN I demonstrated a 75.5% regression rate (the
CIN was completely eradicated) to a negative histology after
twice-weekly administration of bovine-colostrum containing
vaginal tablets (Ginedie®) for 6 months [84]. Another study
in 20 women positively diagnosed with HPV16 infection and
early stage CIN demonstrated complete elimination of the
HPV infection and early stage CIN in 60% of patients treated
with one course of praneem, a polyherbal containing vaginal
tablet, compared to just 10% in the placebo group [85]. Both
of these clinical studies further demonstrate the potential of
localised drug delivery in stopping HPV and early stage CIN
from progressing into cervical cancer.
Vaginal rings
Vaginal rings are torus-shaped drug delivery devices that are
capable of providing controlled delivery of substances to the
vagina for up to a period of 1 to 12 months where it slowly
releases one ormore drugs to provide either a local or systemic
effect [86–89]. Vaginal rings have already seen clinical and
commercial success in contraception (Nuvaring®) [88, 90,
91] and oestrogen replacement therapy (Estring® and
Femring®) [86, 92]. Femring® and Estring® are both
manufactured from silicone elastomer, whereas Nuvaring®
is manufactured from ethylene-vinyl-acetate EVA. The clini-
cal and commercial success of these rings makes them ideal
candidates for the delivery of chemotherapeutic drugs to the
cervix. The vaginal ring overcomes many of the disadvan-
tages associated with gels, tablets and pessaries, which are
often messy, interfere with intercourse and are poorly retained
within the vagina. Boyd et al. describe the development of a
disulfiram releasing vaginal ring that provides diffusion con-
trolled release of DSF for 14 days at levels well in excess of its
IC50 value for the HeLa cervical cancer cell line [93]. This ring
has the potential to release disulfiram for up to 90 days if
required. Keskar et al. developed a cisplatin vaginal ring that
is capable of releasing cisplatin at levels well in excess of its
IC50 for up to 90 days [43]. In vitro testing of the vaginal rings
found them to be just as effective against both HPV positive
and HPV negative cervical cancer, when compared to cisplat-
in alone [43]. This study demonstrates that local drug delivery
of cisplatin to treat cervical cancer has the potential to be just
as effective as systemic delivery.
Cervical caps
The cervical cap is a barrier method of contraception that is
placed over the cervix preventing sperm from entering and
fertilising the egg. The vaginal sponge is also used for contra-
ceptive and is a soft single use device which is soaked in a
spermicide such as nonoxynol-9. A phase II clinical trial of β-
All-trans-retinoic Acid (atRA) delivered via a cervical cap/
vaginal sponge combination in 20 patients demonstrated
50% regression of CIN, with mild systemic and cervical side
effects andmoderate, but tolerable, vaginal side effects [41]. A
randomised phase III clinical trial of atRA delivered via a
cervical cap/vaginal sponge combination in 301 patients
(151 patients with CIN II and 150 patients with CIN III) dem-
onstrated a CIN II regression rate of 43% in the atRA group
compared to just 27% in the placebo group. However, there
was no significant difference between the two arms in the CIN
III patients, demonstrating that the localised delivery of atRA
is effective against moderate CIN but not severe CIN [94]. A
similar result was demonstrated by Ruffin et al. who per-
formed a dosing study of atRA delivered via a cervical cap/
vaginal sponge combination in 175 women with either CIN II
or CIN III. They found that low doses of atRAwere no more
effective than the placebo. However, participants with CIN II
at baseline were more likely to be free of disease at 12 weeks
than participants with CIN III at baseline [95].
Taken together, these three clinical studies demonstrate that
the use of a cervical cap/sponge combination to deliver an
appropriate dose of a chemotherapeutic drug directly to the
cervix can cause CIN I and II to significantly regress and in
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some cases be completely eradicated, thus reducing the pos-
sibility of the patient developing cervical cancer. However,
regression for CIN III was less significant, whichmay bemore
to do with the active ingredient rather than the method of
delivery. A study using the novel cervical cap CerviPrep™,
which was specifically designed for the direct application of
pharmaceuticals to the cervix, demonstrated that it could de-
liver pharmacologically relevant concentrations of
gemcitabine to the cervix of 11 out of the 16 women tested,
with neither gemcitabine nor its metabolites being detected in
the peripheral plasma of any subject [96]. This study demon-
strates that it is possible to deliver effective levels of chemo-
therapeutic drugs to the cervix using localised delivery, while
limiting plasma levels thus reducing systemic toxicities.
Bioadhesive patches
A bioadhesive patch is a drug-loaded patch that is designed to
adhere to the surface of biological tissue, where it provides
sustained topical delivery of a drug within a defined surface area.
For the localised treatment of cervical cancer, the patch would be
applied to the cervix where it would release the chemotherapeutic
drug. Woolfson et al. describe the development of a novel
bioadhesive cervical patch that was capable of providing substan-
tial drug release of the chemotherapeutic drug 5-FU through hu-
man cervical tissue samples for over 20 h [40]. The same group
subsequently evaluated the release of 5-FU from the patch into
cervical tissue and found that tissue concentrations were 100-fold
the concentration required for 5-FU to be cytotoxic against HeLa
cervical cancer cells [97]. These two studies demonstrate that by
using a bioadhesive cervical patch, which actually adheres to the
surface of the cervix, it is possible to deliver effective levels of the
drug into the cervical tissue overcoming some of the issues asso-
ciated with drug diffusion through vaginal mucus.
Sidhu et al. conducted a randomised double-blind controlled
clinical trial on a bioadhesive patch containing the drug 5-FU
[98]. The trial only enrolled patients in which the whole trans-
formation zone was visible and who had CIN I/II; CIN III pa-
tients were excluded on ethical grounds. One hundred patients
were tested with a 5-FU-loaded patch for a 24-h period. The
patch was bilayer containing a vinyl backing onto which a
drug-loaded film was bonded. The film layer was produced
through casting from a 2% w/w Carbopol® gel. The patch was
sufficiently flexible to conform to the shape of the entire cervix.
The patch fulfilled the requirements for the treatment of CIN I/II
without causing any architectural damage. However, the single
dose of 5-FU did not provide effective treatment of the disease,
even though 66% of the 5-FU was released in the first 28 min
and penetrated the cervical tissue to a depth of 5.5 mm.
The author’s explanation for the lack of efficacy is due to
the placebo-controlled group having a 72% spontaneous re-
gression rate of CIN I/II. The study design required that the
spontaneous regression rate was less than 60% with placebo.
The spontaneous regression rate was significantly higher than
previously reported in other studies (14–45%) [99–101].
Newer studies have shown regression rates of up to 58% over
a 2-year period for CIN I [102]. Even the most persistent high-
grade lesions CIN II and CIN III have reported rates of spon-
taneous regression from 6 to 50%, with rate dependent on
diagnosis, and length of time since initial diagnosis [103].
Although not definitive, there is mounting evidence that spon-
taneous regression of CIN is patient-dependent and primarily
determined by the patient’s local immune response to HPV
[104–107].
A further factor postulated by the authors in the study may be
related to the choice of polymeric material to make the film and
that the placebo patch could in itself have aided regression. The
polymer selected was Carbopol®, a resin that has an approximate
pH range of 2.8 to 3.2 in solution.Normal vaginal pH is 4.5 [108].
Thus, this altered pH at the cervical epithelium may have been
sufficient to cause cell death, increasing regression rate. The au-
thors suggest that a future trialmay yield better results should CIN
III patients be included, and a control group who would not
receive a placebo patch. The same group described the develop-
ment of a bioadhesive patch containing IMQ that released signif-
icantly more drug across a model membrane than the proprietary
IMQ cream over a 6-h period [109]. IMQ dosing can vary when
using the proprietary cream due to difference in application
methods and the amount of cream applied. Since the patches
contain a defined drug loading per unit area, they have the poten-
tial of minimising the variations in dosing that is associated with
the cream. Other bioadhesive formulations such as pellets are
currently being investigated for the localised treatment of cervical
cancer [110].
Particulate drug delivery systems
Particulate drug delivery systems, such as nanoparticles and
liposomes, have been investigated for vaginal drug delivery
since they have a number of advantages over more typical
drug depot-based dosage forms. These advantages include
improved sustained release, controlled vaginal absorption,
and improved cellular uptake and targeting [111]. Although
the majority of the research on particulate drug delivery sys-
tems for vaginal drug delivery has focused onHIV prevention,
there have been some examples of it being investigated for the
localised treatment of cervical cancer. Yang et al. describe the
development of biodegradable mucus-penetrating particles
(MPP) that consist of particles coated with Pluronic F127,
which are capable of diffusing rapidly through spaces in the
mucus mesh, compared to uncoated particles which are
immobilised in mucus through adhesive interactions [112].
Paclitaxel-loaded MPPs were shown, using a cervical cancer
mouse model, to distribute throughout the vaginal mucus,
coming in close contact with the tumour, whereas uncoated par-
ticles aggregated in the mucus and were kept away from the
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tumour. As a result, the paclitaxel-loaded MPPs were more ef-
fective at suppressing cervical tumour growth and almost dou-
bled the median survival time of the mice [113]. These MPPs
offer a new and promising platform for the localised treatment of
cervical cancer and may overcome some of the issues associated
with drug diffusion through vaginal mucus.
Zenget al. developednanoparticles consistingof acholic acid
functionalised, star-shaped block copolymer of PLGA and vita-
min E TPGS for the sustained and controlled delivery of doce-
taxel [114]. These nanoparticles had superior in vitro and in vivo
performance when compared with conventional PLGA nano-
particles and linear PLGA-b-TPGS copolymer nanoparticles,
with a significantly higher cellular uptake and antitumour effi-
cacy [114]. This may be as a result of their smaller size when
compared to the conventional PLGA nanoparticles and linear
PLGA-b-TPGS copolymer nanoparticles [114], demonstrating
the importance of size when it comes to formulating nanoparti-
cles for the localised treatment of cervical cancer.
Saengkrit et al. demonstrated increased cellular uptake and
cytotoxicty of liposomal curcumin compared to free curcumin
in both HeLa and SiHa cell lines [115]. Furthermore, by making
the liposomal curcumin cationic through surface modification
with various compositions of didecyldimethylammonium bro-
mide (DDAB), cholesterol and non-ionic surfactant increased
its anticancer efficiency. This study demonstrates the potential
of liposomal formulations in enhancing the cellular uptake of
hydrophilic drugs improving their anticancer efficiency and
through surface modification of the liposome, cellular uptake
and anticancer efficiency can be further enhanced. Chen et al.
compared paclitaxel-loaded multi-layered liposomes with the
same liposome only coated with anionic polyacrylic acid
(PAA) followed by cationic chitosan [116]. They demonstrated
that the coated liposomes exhibited a more sustained release of
paclitaxel as well as an enhanced cytotoxicity in human cervical
cancer cell lines compared to the uncoated liposomes [116]. This
is further evidence, which demonstrates that the anticancer effi-
ciency of particulate drug delivery systems can be enhanced
through either modifying or coating their surface. However, sig-
nificant variability has been observed, in both preclinical and
clinical studies, of tumour accumulation and intra-tumoural dis-
tribution with liposomes [117–120]. Stapleton et al. demonstrat-
ed using two mouse xenograft tumour models of cervical cancer
that regions with higher tumour perfusion have a greater degree
of liposome accumulation [121]. These findings demonstrate that
by determining tumour perfusion, it may be possible to select
patients who are more likely to respond to liposome and other
particulate-based therapies.
Conclusion
Cervical cancer is the third most prevalent cancer in women
globally and is especially dominant in developing countries due
to a lack of screening, prevention and control programs.
Treatment depends on the stage of the cancer and whether or
not the woman would like the option to be able to have children
after treatment. Most treatment regimens will involve surgery to
remove the cancerous tissue, but the technique may vary. Some
treatment regimens, particularly those used to treat more ad-
vanced stage cancers, may involve additional adjuvant chemo
or radiotherapy. Vaginal drug delivery devices and formulations
could be utilised to provide localised delivery of chemotherapeu-
tic drugs to the cervix.
As of yet, none of the drug delivery systems described in
this review are approved for first-line treatment of precancer-
ous or early stage cervical cancer. Nevertheless, localised de-
livery of chemotherapeutic drugs directly to the cervix has the
great potential to improve patients’ overall quality of life both
during and after treatment as a result of direct delivery to the
site of action, which results in a lower dose being required and
a reduction in systemic side effects. Certainly, since there is an
increasing reluctance to treat CIN I, CIN II and even CIN III
surgically in young women who wish for future pregnancy,
the most logical approach is to find pharmacological means to
reduce the size or completely eradicate the abnormal tissue.
Precision medicine is another incentive for localised delivery,
as this approach will require treatment with combination ther-
apy to knockout the multiple molecular pathways that support
cancer cell growth.
Furthermore, since cervical cancer is such a significant bur-
den in the developing world, there must be additional motiva-
tionin the researchcommunity todevelopadeliverysystemthat
canunderpincryotherapy anddoso in the context of singlevisit
treatments.Themost logical approachwouldbe to learn lessons
from the microbicides field and the fight against the HIV epi-
demic.Vaginal ringshavebeenshown tobeacost-effective and
efficacious means for controlled drug delivery in low-resource
settings [122].Can a vaginal ring or a similar device be given to
patients in low-resource settings that will provide a level of
treatment sufficient to increase regressionrates andhence lower
mortality rates in these countries?
It is not so much a device that requires significant develop-
ment, but instead, it is the identification of a cocktail of well-
tolerated drugs that can be combined in a single device that
can be safely worn for extended periods of time and with
limited clinical intervention. Disulfiram could be one such
drug, given its long history in clinical use, but there are even
more drugs that could be suitable for such repurposing, in-
cluding aspirin, metformin and itraconazole, which are being
investigated for anti-cancer properties. It is our contention that
there already exists the framework for an intravaginal device
for the treatment of cervical cancer in the developing world.
Instead what is required is the willpower of the funding bodies
and the research community to articulate and bring to fruition
a better, more effective means of treatment that can run in
tandem with existing efforts to increase screening of the
Drug Deliv. and Transl. Res.
disease, and consequently drive down the dreadful mortality
rates in these countries.
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